News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AMAG Pharmaceuticals, Inc. (AMAG) Enters into Anemia Drug Licensing Deal with Takeda Pharmaceutical Co. Ltd. (TKPYY); AMAG to Get $60 Million Upfront, Eligible for $220 Million in Milestone Payments



4/1/2010 6:33:27 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG - News) will host a conference call and webcast today at 8:00 am ET to discuss today’s announcement that AMAG Pharmaceuticals, Inc. and Takeda Pharmaceuticals Company have entered into a strategic collaboration agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications in select ex-US territories.

AMAG Conference Call and Webcast Access

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on April 1, 2010 through midnight April 2, 2010. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 64493010.

The call will be webcast and accessible through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on April 1, 2010 through midnight April 15, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

Contact:

AMAG Pharmaceuticals Amy Sullivan, +1-617-498-3303 or Carol Miceli, +1-617-498-3361


Read at Reuters
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES